Craig Tipple

Dr Craig Tipple joined DNDi as Medical Director in May 2021. His infectious disease, scientific, and drug development knowledge and experience will greatly contribute to DNDi’s development of treatments for neglected diseases and neglected populations.

Craig is a British physician scientist. He is a member of the Royal College of Physicians and holds diplomas in HIV and Genitourinary Medicine. As a doctor, he has cared for people living with HIV in London for over 12 years. He undertook his doctoral research at the Imperial College London where he studied better ways of monitoring treatment responses in people with syphilis. This research took him to Uganda and Sri Lanka where he set up collaborative research projects. 

In 2016, Craig joined the pharmaceutical company GlaxoSmithKline in their infectious diseases unit and worked on developing new antibiotics and treatments for hepatitis B and other viral diseases. Prior to joining DNDi, he worked as Medical Director of GSK’s Phase I trials unit and led early phase R&D projects in ID. Most recently, Craig served as Global Clinical Development lead for an anti-viral monoclonal antibody for COVID-19 treatment that GSK is developing in partnership with Vir Biotechnology.